Under the agreement, RTI Biologics will process soft tissue allograft and xenograft implants to help patients in ENT applications for distribution by ENTrigue. Long term, the two companies will co-develop novel biologic solutions for ENTrigue’s surgeons and patients.
Brian Hutchison, chairman and CEO of RTI Biologic, said: “We are pleased to offer biologic membrane tissues for ear, nose and throat applications through ENTrigue. We felt that ENTrigue was the right distributor for us in this market – ENTrigue’s management team has well over 100 years of collective experience and success in the ENT surgical market and, like RTI, places an emphasis on innovative solutions for surgeons and patients.
“Working together, ENTrigue and RTI can bring biologic alternatives to patients while working to maximize each gift of donated tissue.”